Raben David 4

4 · Bicara Therapeutics Inc. · Filed Mar 5, 2026

Form 4

Period: 2026-03-03

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-03$3.79/sh+200$758→ 55,486 total
Sale
Common Stock
[F1]
2026-03-03$18.45/sh−200$3,690→ 55,286 total
Exercise/Conversion
Common Stock
[F1]
2026-03-04$3.79/sh+16,300$61,774→ 71,586 total
Sale
Common Stock
[F1][F2]
2026-03-04$18.52/sh−16,300$301,920→ 55,286 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]
2026-03-03−200→ 69,213 total
Exercise: $3.79Exp: 2023-08-08→ Common Stock (200 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]
2026-03-04−16,300→ 52,913 total
Exercise: $3.79Exp: 2023-08-08→ Common Stock (16,300 underlying)

Footnotes (3)

[F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.45 to $18.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
[F3]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Signature

/s/ Lara Meisner, Attorney-in-Fact|2026-03-05

Documents

1 file